Réponse osseuse aux traitements hormonaux utilisés en gynécologie

Reproduction Humaine et Hormones

Volumn 11, Issue 10, 1998, Pages 796-807

  Tamborini, Alain ^a   Ruiz, Jean Charles ^a  

^a Hopital Boucicaut   (France)

Author keywords

Estrogen; Gnrh agonist; Menopause; Osteoporosis; Progestin; SERM; Tibolone

Indexed keywords

AROMATASE INHIBITOR; CYPROTERONE ACETATE; DANAZOL; ESTROGEN; ETHINYLESTRADIOL; GONADORELIN AGONIST; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; RALOXIFENE; TAMOXIFEN; TIBOLONE;

BONE ATROPHY; BONE DENSITY; BONE MINERALIZATION; DRUG MECHANISM; ESTROGEN DEFICIENCY; FEMALE; HORMONE SUBSTITUTION; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOPENIA; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032415882     PISSN: 09943919     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. AITKEN JM, HAïT DM, LINDSAY R. :Oestrogen replacement therapy for prevention of osteoporosis after oophorectomy. BrMeclJ, 1973, SISSIS.
2. BAZIN B, THEVENOT R, BURSAUX C, PARIS J. :Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J .Obstet Gynaecol, 1987,94,12,1199-1204.
3. BERNIXG B, KUIJK CV, KUIPER JW, BENNINK HJ, KICOVIC PM, FAUSER BC. :Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women : a two-year randomized, placebo-controlled study. Bone, 1996,19,395-399.
4. BJARNASON NH, BJARNSON K, HAARBO J, ROSENQUIST C, CHRISTIANSEN C. :Tibolone : pre-vention of bone loss in late postmenopausal women. J Clin Endocrinol Metab, 1996,81,2419-2422.
5. BLACKER C, SENET JM, DUBOURG D, DENIS:RIGAUD C, FOURTILLAN JB. :Action de la promegestone àla dose de 0.5 mg par jour, 20 jours par mois sur le pic ovulatoire de LH. Horm Reprod Metab, 1986,3,277-282.
6. BOWMAN BM, MILLER SC. :Elevated progesterone during pseudopregnancy may prevent bone loss associated with low estrogen. J Bone Miner Res, 1996, 11, 15-21.
7. BROULIK PD, STARKA L, PACOVSKY V. :Effect of antiandrogen (cyproterone acetate) on the action of testosterone on bone protein. Endocrinol Exp, 1976, 10,211-216.
8. CHRISTENSEN MS, HAGEN C, CHRISTIANSEN C, TRANSBOL I. :Dose- response evaluation of cyclic estrogen/gestagen in postmeno pausal women. Placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol, 1982, 144, 873-879.
9. CHRISTIANSEN C, CHRISTENSEN MS, McNAiR P, HAGEN C, STOCKLUNDKE, TRANSBOL I. :Prevention of early postmenopausal bone loss. Controlled 2-years study in 315 normal females. Eur J Clin Invest, 1980, 10,273-279.
10. Consensus Development Conference - Diagnosis, Prophylaxis and Treatment of Osteoporosis. Am J Med, 1993, 94, 646-650.
11. CUNDY T, CORNISH J, EVANS MC, ROBERTS H, REID IR. :Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ, 1994, 308, 247-248.
12. CUNDY T, EVANS M, ROBERTS H, WATTIE D, AMES R, REID IR. :Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ, 1991, 303, 1316.
13. CUNDY T, FARQUHAR CM, CORNISH J, REID IR. :Short-term effects of high dose oral medroxyprogcsterone acetate on bone density in premenopausal women. J din Endocrinol Mctab, 1996,81, 1014-1017.
14. DAWOOD MY. :Hormonal therapies for endometriosis: implications for bone metabolism. Acta Obstet Gynecol Scand Suppl, 1994,159,22-34.
15. DELMAS PD. :Biochemical markers of bone turnover : theoretical considerations and clinical use in osteoporosis. Am J Med 1993,95, 11S-16S.
16. DELMAS PD. :Two new studies show Menorest increase bone mass.Communication IV European Consress on Menopause, Vienne, 10 Octobre 1997.
17. DELMAS PD, BJARNASSON NH, MITLAK BH, RAVOUX AC, SHAH AS, HUSTER WJ, DRAPER M, CHRISTIANSEN C. :Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in post menopausal women. A/ Eng J Med, 1997, 337, 1641-1647.
18. DMOWSKI WP, RANA N, PEPPING P, CAIN DF, CLAY TH. :Excretion of urinary N-telopeptides reflects changes in bone turnover during ovarian suppression and indicates individually variable estradiol threshold for bone loss. Fertil Steril, 1996,66,929-936.
19. DRAPER MW, FLOWERS DE, HUSTER WJ, NEILD JA, HARPER KD, ARNAUD C. :A controlled trial of raloxifene (LY139481) HCI : impact on bone turnover and serum lipid profile in healthy post menopausal women. J Bone Miner Res, 1996, 11,835-842.
20. ELDRED JM, HAYNES PJ, THOMAS EJ. :A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisterone. 1 Clin Endocrinol, 1992, 37, 354-359.
21. ERDTSIECK RJ, POLS HAP, VAN KUIJK C, BIRKENHAGER-FRENKEL DH, ZEELENBERG J, KOOY PP, MULDER P, . BIRKENHAGER JC. :Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res, 1994,9,277-283.
22. ETTINGER B, GENANT HK, STEIGER P, MADVIG P. :Low dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol, 1992,166,479-488.
23. EVANS SF, DAVIE MW. :Low and conventional dose transdermal oes-tradiol are equally effective at preventing bone loss in spine and femur at all post-menopausal ages. Clin Endocrinol, 1996,44,79-84.
24. FELDMANN S, MINNE HW, PARVIZI S, PFEIFER M, LEMPERT UG, BAUSS F, ZIEGLER R. :Antiestrogen and anti. androgen administration reduce bone mass in the rat. Bone Miner, 1989,7,245-254.
25. FELSON DT, ZHANG Y, HANNAN MT, KIEL DP, WILSON PWF, ANDEUSON JJ. :The effect of post menopausal estrogen therapy on bone density in elderly women. N Eng J Med, 1993, 329, 1141-1146.
26. FIELD CS, ORY SJ, WAHNER HW, HERRMANN R, JUDD, RIGGS BL. :Preventive effects of transdennal 17 beta-estradiol on osteoporotic changes after surgical menopause : a two year placebo-controlled trial. Am J Obstet Gynecol, 1993, 168, 114-121.
27. FRIEDMAN AJ, DALY M, JUNEAUNORCROSS M, GLEASON R, REIN MS, LEBOFF M. :Long-term medical therapy for Iciomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back'for 2 years. Hum Reprod, 1994,9, 1618-1625.
28. GAMBACCIANI M, SPINETTI A, ORLANDI R, PIAGGESI L, CAPPAGLI B, WEISS C, CIAPONI M, GENAZZANI AR. :Effects of a new estrogen/progestin combination in the treatment of postmenopausal syndrome. Maturitas, 1995,22(2), 115-120.
29. GARNERO P, SORNAY-RENDU E, DELMAS PD. :Decreased bone turnover in oral contraceptive users. Bone, 1995,16(5),499-503.
30. GEUSENS P, DEQUEKER J, GIELEN J, SCHOT LP. :Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas, 1991, 13, 155-162.
31. GOTFREDSEN A, ClIRISTIANSEN C, PALSHOF T. :The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer. Cancer, 1984,'53, 853-857.
32. GREY AB, CUNDYT, EVANS M, REID I. :Medroxyprogesterone acetate enhances the spinal bone mineral density response to oestrogen in late post-menopausal women. Clin Endocrinol, 1996,44,293-296.
33. GREY AB, STAPLETON JP, EVANS MC, TATNELL MA, AMES RW, REID IR. :The effect of the antiestrogen tamoxifen on bone mineral densi ty in normal late postmenopausal women. Am J Med, 1995, 99, 636641.
34. HASSAGER C, JENSEN SB, CHRISTIANSEN C. :Non-responders to hormone replacement therapy for the prevention of postmenopausal bone loss: do they exist? Osteopoms Int, 1994,4,36-41.
35. HOROWITZ M, WISHART JM, NEED AG, MORRIS HA, NORDIN BE. :Effects of norethisterone on bone related biochemical variables and forearm bone mineral in post-menopausal . osteoporosis. Clin Endocrinol, 1993,39,649-655.
36. HORSMAN A, JONES M, FRANCIS R, NORDIN C. :The effect of estrogen dose on postmenopausal bone loss. N Engl J Mal, 1983, 309, 14051407.
37. JILKA RL, HANGOC G, GIRASOLE G, PASSERI G, WILLIAMS DC, ABRAMS JS, BOYCE B, BROXMEYER H, MANOLAGAS SC. :Increased ostcoclast development after estrogen loss: mediation by interleukin-6. Science, 1992,257,88-91.
38. KIEL DP, FELSON DT, ANDERSON JJ, WILSON PWF, MOSKOWITZ MA : Hip fracture and the use of estrogens in post-menopausal women. ' The Framingham study. N Engl J Med, 1987,317,1169-1174.
39. LAITINEN K, VALIMAKI M, KETO P. :Bone mineral density measured by dual-energy x-ray absorptiometry in healthy Finnish women. Calcif Tissue Int, 1991,48, 224-23 L
40. LlNDSAY R, AlTKEN JM, ANDERSEN JB, HART DMM, MACüONALD EB, CLARKE AC. :Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976, 1, 1038-1040.
41. LINDSAY R, HART DM, CLARK DM. :The minimum effective dose of estrogen for prevention of postmenopausal bone. Obstet -Gynecol, 1984, 63, 754-763.
42. LIPPUNER K, HAENGGI W, BIRHAEUSER MH, CASEZ JP, JAEGER P. :Prevention of postmenopausal bone 1055 using tibolone or conventional peroral or transdermal hormone replacement therapy with 17betaestradiol and dydrogesterone. J Bone Miner Res, 1997, 12 (5), 806-812.
43. LOVE RR, BARDEN HS, MAZESS RB, EPSTEIN S, CHAPPELL RJ. :Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med, 1994, 154, 2585-2588.
44. MAIS V, FRUZZETTI F, AJOSSA S, PAOLETTI AM, GUERRIERO S, MELIS GB. :Bone metabolism in young women taking a monophasic pill containing 20 meg ethinylestradiol: a prospective study. Contraception, 1993,48 (5), 445-452.
45. MARIE P, DE VERNEJOUL MC. :Facteurs svstémiques et locaux du remodelaae osseux in Maladies métaboliques osseuses de l'adulte, Kuntz D, Flammarion-MédectneSciences Ed, Paris 1996, pp 49-68.
46. MIZUNUMA H, OKANO H, SODA M, RAGAMI I, MIYAMOTO S, TOKIZAWA T, HONJO S, IBUKI Y. :Prevention of post menopausal bone loss with minimal uterine bleedind using low dose continuous estrogen/progestin therapy : a 2-year prospeative study. Maturitas, 1997, 27, 1, 69-76.
47. MORISHIMA A, GRUMBACH MM, SIMPSON ER, FISHER C, QIN K. :Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Enilocrinol Metab, 1995, 80, 3689-3698.
48. NORDIN BEC, NEED AG, CHATTERTON BE, HOROWITZ M, MORRIS HA. :The relative contributions of age and years since menopause to post menopausal bone loss. J Clin Endocrinol Metab, 1990, 70, 83-88.
49. PALACIOS S, MENENDEZ C, JURADO AR, VARGAS JC. :Effects of percutaneous oestradiol versus oral oestrogens on bone density. Maturitas, 1995,20,209-213.
50. POWLES TJ, HICKISH T, KANIS JA, TIDY A, ASHLEY S. :Effect of tamoxifen on bone mineral den- sity measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol, 1996, 14, 78-84.
51. PRIOR JC, VIGNA YM, BARR SI, REXWORTHY C, LENTLE BC. :Cyclic medroxyprogesterone treatment increases bone density: a controlled trial in active women with menstrual cycle disturbances. Am J Mecl, 1994, 96,521-530.
52. RIBOT C. :Be'neTices tardifs du traitement hormonal substitutif. Reproduction Humaine et Hormones, 1994, 8, 363-367.
53. RIBOT C, TRéMOLLIèRES F, FOUILLES JM. :Prevention of post menopausal bone loss by long-term parenteral administration of 17 beta estradiol : comparison of percutaneous and transderrmal route. In : De Luca H, Mazess R Ed,. Ostcoporosis. Physiological basis, assessment and treatment. Elsevier, Amsterdam, 1989, pp 137-145.
54. RIBOT C.TRéMOLLIERES F, FOUILLES JM. :Traitement hormonal et pré vention de l'ostéoporosc post-ménopausique : analyse critique, in Evaluation des traitements de la ménopause, Springer-Verlag ed, Paris 1992, pp 61-71.
55. RlIS BJ, OVERGAARD K, CHRISTIANSEN C. :Biochemical markers of bone turnover to monitor the bone response to postmenopausal hormone replacement therapy. Osteopomsis Int, 1995,5, 276-280.
56. RIIS BJ, THOMSEN K, STROM V, CHRISTIANSEN C. :The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol, 1987,156,61-65.
57. Roux C, KOLTA S, CIIAPPARD C, MORIEUX C, DOUGADOS M, DE VERNEJOUL MC. :Bone effects of dydrogesterone in ovariectomized rats: a biologic, histomorphometric, and densitometric study. Bone, 1996, 19,463-468.
58. Roux C, PELISSIER C, LISTRAT V, KOLTA S, SIMONETTA C, GUIGNARD M, DOUGADOS M, AMOR B. :Bone loss during gonadotropin releasing hormone agonist treatment and use of nasal calcitonin. Osteoporos Int, 1995,5, 185-190.
59. RUE JC. :Les posologies modérées d'oestrogènes peuvent-elles protéger de l'ostéoporose ? Reproduction Humaine et Hormones, 1996, IX, n° specials, 13-20.
60. Ruiz JC, CORMIER C, ROZENBAUM . H, MENKèS CJ. :Evaluation du risque ostéoporotique en pratique gynécologique in Imagerie clinique en Gynécologie, Buthiau D et Dargent D, Vigot-Maloine Ed, Paris 1993, pp 351-362.
61. Ruiz JC, Tamborini A, Neftel P, Bosio-Le Goux B, Lecuru F, Taurelle R : Variabilité de la réponse osseuse àl'intauration d'une honnonothérapie substitutive. Rev Fr Gynccol Obstet, 1995,90,263-274.
62. SATO M, MCCLINTOCK C, KIM J, TURNER CH, BRYANT HU, MACHE D, SLEMENDA CW. :Dual-Energy X-ray Absorptiometry of Raloxifene effects on the lumbar vertebrae an femora of ovariectomized rats. J Bone Miner Res, 1994, 9, 715-724.
63. SCHNEIDER DL, BARRETT-CONNOR EL, MORION DJ. :Timing of post menopausal estrogen for optimal bone mineral density.The Rancho Bernardo Study. JAMA, 1997, 277, 543-547.
64. The Writing Group for the PEPI. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA, 1996,276,1389-1396.
65. TRéMOLLIèRES F, POUILLES JM, RIBOT C. :Effect of long term administration of progestogen on postmenopausal bone loss : result of a two year controlled randomized study. Clin Endocrinol, 1993, 38, 627-631.
66. TUPPURAINEN M, KROGER H, SAARIKOSKI S, HONKANEN R, ALHAVA E. :The effect of pre- vious oral contraceptive use on bone mineral density in perimenopausal women. Osteopomsis lut, 1994, 4, 93-98.
67. VANDERSCHUEREN D, VAN HERCK E, Nus J, EDERVEEN AG, DE COSTER R, BOUILLON R. :Aromatase inhibition impairs skeletal modeling and decreases bone mineral density in growing male rats. Endocrinology, 1997,138,2301-2307.
68. WARD RL, MORGAN G, DALLEY D, KELLY PJ. :Tamoxifen reduces bone turnover and prevents Inmbar spine and proximal femonl bone loss in early postmenopausal women. Bone Miner, 1993, 22, 87-94.
69. WATTS N, REBAR R, GENANT H, BRèNNAN J, SILFEN S, YANG HM, NôLAN J. :The Relationship of Plasma Estradiol Levels to BMD Changes in a Clinical Study of Esterified Estrogens in Postmenopausal Women. Poster session ASBMR 19th Annual Meeting, Cincinnati, September 10-14, 1997.
70. WEISS NS, URE CL, BALLARD JH, WILLIAMS AR, DALING JR. :Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. W Engl J Mcd, 1980,303, 1195-1198.
71. ZAMBERLAN N, CASTELLO R, GATTI D, ROSSINI M, BRAGA V, FRACASSI E, ADAMI S. :Intermittent Etidronate partially prevents bone loss in hirsute hyperandrogenic women treated with GnRH agonist. Osteoporos Int, 1997,7,133-137.